Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

Infections

A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets

This plain language summary from Neurodegenerative Disease Management describes the MAGNIFY-MS study, which investigated whether cladribine tablets affect how well the body responds to flu and chickenpox virus vaccines in people with multiple sclerosis.

Read the full article here.

The original article on which this plain language summary is based is titled ‘Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis’ and was published in the Multiple Sclerosis Journal. Read the original article here.

Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old

This plain language summary from Future Virology describes part of a clinical study of the Pfizer-BioNTech COVID-19 vaccine. The part of the study described was focused on participants 12- to 15-years old and was ongoing at the time of publication, meaning the final results may be different from the results included in this summary.

Read the full article here.

The original article on which this plain language summary is based is titled ‘Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents’ and was published in the New England Journal of Medicine. Read the original article here.

Plain language summary of Pfizer-BioNTech BNT162b2 COVID-19 vaccine safety in participants 16 years or older and protection against COVID-19 in participants 12 years or older

This plain language summary from Future Virology describes part of a clinical study of the Pfizer-BioNTech COVID-19 vaccine. The part of the study described was ongoing at the time of publication, meaning the final results may be different from the results included in this summary.

Read the full article here.

The original article on which this plain language summary is based is titled ‘Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months’ and was published in the New England Journal of Medicine. Read the original article here.

Study of an antifungal medicine isavuconazole used in treatment of mold infections in China: A plain language summary

This plain language summary from Future Microbiology describes the results of a Chinese study into the use of isavuconazole in the treatment of mold infections.

Read the full article here.

The original article on which this plain language summary is based is titled ‘In vitro Activity of Isavuconazole and Comparators Against Clinical Isolates of Molds from a Multicenter Study in China’ and was published in the journal Infection and Drug Resistance. Read the original article here.

Plain language summary of Pfizer-BioNTech BNT162b2 COVID-19 vaccine safety in participants 16 years or older and protection against COVID-19 in participants 12 years or older

This new plain language summary in Future Virology looks at the latest findings on the role of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine.

Read the full article here.

The original article on which this summary is based is called ‘Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months’ and was originally published in the journal The New England Journal of Medicine. The original article can be read here.